Hood River Capital Management LLC Acquires 13,710 Shares of Haemonetics Co. (NYSE:HAE)

Hood River Capital Management LLC boosted its holdings in shares of Haemonetics Co. (NYSE:HAE - Free Report) by 6.8% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 214,290 shares of the medical instruments supplier's stock after buying an additional 13,710 shares during the period. Hood River Capital Management LLC owned approximately 0.43% of Haemonetics worth $16,732,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in HAE. Arizona State Retirement System boosted its position in Haemonetics by 1.2% during the 4th quarter. Arizona State Retirement System now owns 14,853 shares of the medical instruments supplier's stock valued at $1,160,000 after buying an additional 181 shares during the period. Parkside Financial Bank & Trust lifted its holdings in shares of Haemonetics by 25.6% during the fourth quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier's stock valued at $92,000 after purchasing an additional 240 shares during the last quarter. HighTower Advisors LLC boosted its position in shares of Haemonetics by 7.8% in the 4th quarter. HighTower Advisors LLC now owns 3,353 shares of the medical instruments supplier's stock worth $262,000 after purchasing an additional 244 shares in the last quarter. TD Waterhouse Canada Inc. bought a new stake in Haemonetics in the fourth quarter worth $25,000. Finally, Xponance Inc. grew its stake in shares of Haemonetics by 5.9% in the fourth quarter. Xponance Inc. now owns 7,246 shares of the medical instruments supplier's stock worth $566,000 after acquiring an additional 404 shares during the last quarter. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Haemonetics Stock Performance

Shares of NYSE HAE traded down $0.55 during trading on Monday, hitting $61.97. The company had a trading volume of 95,067 shares, compared to its average volume of 688,675. Haemonetics Co. has a 12 month low of $55.30 and a 12 month high of $97.97. The company has a debt-to-equity ratio of 1.35, a quick ratio of 2.55 and a current ratio of 3.97. The firm has a market capitalization of $3.11 billion, a P/E ratio of 24.38, a price-to-earnings-growth ratio of 1.11 and a beta of 0.41. The stock has a 50 day simple moving average of $62.83 and a 200 day simple moving average of $72.11.

Haemonetics (NYSE:HAE - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. As a group, analysts anticipate that Haemonetics Co. will post 4.55 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have weighed in on HAE. Raymond James restated a "strong-buy" rating and set a $115.00 price objective (down from $120.00) on shares of Haemonetics in a research note on Friday, February 7th. Bank of America downgraded Haemonetics from a "neutral" rating to an "underperform" rating and reduced their price objective for the stock from $95.00 to $68.00 in a report on Friday, February 7th. Barrington Research reduced their price target on shares of Haemonetics from $108.00 to $95.00 and set an "outperform" rating for the company in a research note on Friday, February 7th. StockNews.com downgraded shares of Haemonetics from a "buy" rating to a "hold" rating in a research report on Saturday, February 15th. Finally, JMP Securities decreased their target price on shares of Haemonetics from $125.00 to $100.00 and set a "market outperform" rating for the company in a research note on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Haemonetics currently has an average rating of "Moderate Buy" and a consensus target price of $101.22.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.